Showing results (131-140 of 1,674) with videos related to
Sort By:
Pageof 168
Neurology(R) Neuroimmunology & Neuroinflammation|February 2, 2022
Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease ProgressionPaolo Preziosa, Elisabetta Pagani, Alessandro Meani, et al.Journal of Neurology|April 7, 2023
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational studyChiara Zanetta, Maria A Rocca, Alessandro Meani, et al.Human Brain Mapping|June 13, 2006
Influence of body segment position during in-phase and antiphase hand and foot movements: a kinematic and functional MRI studyMaria A Rocca, Roberto Gatti, Federica Agosta, et al.Journal of Neurology|March 20, 2024
Thalamic nuclei volume partially mediates the effects of aerobic capacity on fatigue in people with multiple sclerosisMatteo Albergoni, Elisabetta Pagani, Paolo Preziosa, et al.Neurology(R) Neuroimmunology & Neuroinflammation|May 12, 2026
Functional Connectivity Alterations of the Central Autonomic Network in Multiple Sclerosis: Links to Fatigue and Aerobic Training EffectsGiorgio Guido, Paola Valsasina, Tetsu Morozumi, et al.Frontiers in Neurology|April 19, 2024
Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in ItalyMassimo Filippi, Laura Ferrè, Chiara Zanetta, et al.Neuroimage|February 22, 2003
Demyelination and cortical reorganization: functional MRI data from a case of subacute combined degenerationMassimo Filippi, Maria A Rocca, Paolo Rossi, et al.Neuroimage|May 27, 2008
A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypesAntonia Ceccarelli, Maria A Rocca, Elisabetta Pagani, et al.The New England Journal of Medicine|March 16, 2012
Placebo-controlled trial of oral laquinimod for multiple sclerosisGiancarlo Comi, Douglas Jeffery, Ludwig Kappos, et al.Journal of Neurology, Neurosurgery, and Psychiatry|March 1, 2020
Two-year regional grey and white matter volume changes with natalizumab and fingolimodPaolo Preziosa, Maria A Rocca, Elisabetta Pagani, et al.Pageof 168